Related Experiment Video

Updated: Nov 4, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K

Down-Regulating the Expression of miRNA-21 Inhibits the Glucose Metabolism of A549/DDP Cells and Promotes Cell Death

Ye Sun1,2, Wenjun Liu3, Qiuyu Zhao4

  • 1Department of Cell Biology, College of Integrated Chinese and Western Medical, Liaoning University of Traditional Chinese Medicine, Shenyang, China.

Frontiers in Oncology
|May 28, 2021
PubMed

Insights

MicroRNA-21 (miRNA-21) is highly expressed in cisplatin-resistant lung cancer cells and promotes drug resistance. Inhibiting miRNA-21 with cisplatin may enhance treatment efficacy by reducing glycolysis and promoting cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • MicroRNA-21 (miRNA-21) is implicated in various cancers, affecting proliferation, metastasis, and drug resistance.
  • Cisplatin resistance is a significant challenge in treating non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To investigate the mechanism of miRNA-21 in cisplatin-resistant A549/DDP cells.
  • To evaluate the combined effect of miRNA-21 inhibition and cisplatin on NSCLC cells.

Main Methods:

  • RNA sequencing and quantitative real-time PCR (qRT-PCR) to assess miRNA-21 expression.
  • Analysis of glycolysis, enzyme activity, and cell death in A549/DDP cells treated with miRNA-21 and cisplatin.
  • Investigation of the PI3K/AKT/mTOR/HIF-1α signaling pathway.

Main Results:

  • miRNA-21 was significantly upregulated in cisplatin-resistant A549/DDP cells compared to A549 cells.
  • Combined treatment with miRNA-21 and cisplatin inhibited glycolysis and reduced key glycolytic enzyme expression.
  • The combination therapy promoted A549/DDP cell death and excessively inactivated the PI3K/AKT/mTOR/HIF-1α pathway.

Conclusions:

  • miRNA-21 plays a crucial role in cisplatin resistance in NSCLC by influencing glycolysis and cell survival.
  • Reducing miRNA-21 expression alongside cisplatin chemotherapy may represent a promising therapeutic strategy for NSCLC.
  • This study provides a theoretical basis for targeting miRNA-21 in combination with cisplatin for improved NSCLC treatment outcomes.
Keywords:
PI3K/AKT/mTORcisplatin resistanceglycolysismiRNA-21non-small cell lung cancer

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.6K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.8K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K